Association of suicide attempts with acne and treatment with isotretinoin: retrospective Swedish cohort studyBMJ 2010; 341 doi: https://doi.org/10.1136/bmj.c5812 (Published 12 November 2010) Cite this as: BMJ 2010;341:c5812
- Anders Sundström, pharmacoepidemiologist123,
- Lars Alfredsson, professor in epidemiology4,
- Gunilla Sjölin-Forsberg, dermatologist and clinical pharmacologist2,
- Barbro Gerdén, dermatologist, senior expert2,
- Ulf Bergman, clinical pharmacologist3, visiting professor1,
- Jussi Jokinen, senior psychiatrist5
- 1Centre for Pharmacoepidemiology, Karolinska Institute, Karolinska University Hospital T2, 171 76 Stockholm, Sweden
- 2Medical Products Agency, 751 03 Uppsala, Sweden
- 3Division of Clinical Pharmacology, Karolinska Institute
- 4Institute of Environmental Medicine, Karolinska Institute
- 5Department of Clinical Neuroscience, Psychiatry Section, Karolinska Institute
- Correspondence to: A Sundström
- Accepted 6 September 2010
Objective To assess the risk of attempted suicide before, during, and after treatment with isotretinoin for severe acne.
Design Retrospective cohort study linking a named patient register of isotretinoin users (1980-9) to hospital discharge and cause of death registers (1980-2001).
Setting Sweden, 1980-2001.
Population 5756 patients aged 15 to 49 years prescribed isotretinoin for severe acne observed for 17 197 person years before, 2905 person years during, and 87 120 person years after treatment.
Main outcome measures Standardised incidence ratio (observed number divided by expected number of suicide attempts standardised by sex, age, and calendar year), calculated up to three years before, during, and up to 15 years after end of treatment.
Results 128 patients were admitted to hospital for attempted suicide. During the year before treatment, the standardised incidence ratio for attempted suicide was raised: 1.57 (95% confidence interval 0.86 to 2.63) for all (including repeat) attempts and 1.36 (0.65 to 2.50) counting only first attempts. The standardised incidence ratio during and up to six months after treatment was 1.78 (1.04 to 2.85) for all attempts and 1.93 (1.08 to 3.18) for first attempts. Three years after treatment stopped, the observed number of attempts was close to the expected number and remained so during the 15 years of follow-up: standardised incidence ratio 1.04 (0.74 to 1.43) for all attempts and 0.97 (0.64 to 1.40) for first attempts. Twelve (38%) of 32 patients who made their first suicide attempt before treatment made a new attempt or committed suicide thereafter. In contrast, 10 (71%) of the 14 who made their first suicide attempt within six months after treatment stopped made a new attempt or committed suicide during follow-up (two sample test of proportions, P=0.034). The number needed to harm was 2300 new six month treatments per year for one additional first suicide attempt to occur and 5000 per year for one additional repeat attempt.
Conclusions An increased risk of attempted suicide was apparent up to six months after the end of treatment with isotretinoin, which motivates a close monitoring of patients for suicidal behaviour for up to a year after treatment has ended. However, the risk of attempted suicide was already rising before treatment, so an additional risk due to the isotretinoin treatment cannot be established. As patients with a history of suicide attempts before treatment made new attempts to a lesser extent than did patients who started such behaviour in connection with treatment, patients with severe acne should not automatically have isotretinoin treatment withheld because of a history of attempted suicide.
Since 1 April 2010, GS-F has held the position of secretary-general of the Council for International Organizations of Medical Sciences (CIOMS). AS, GS-F, and BG are affiliated to the Medical Products Agency; the views expressed are those of the authors and are not necessarily those of the MPA.
Contributors: AS, GS-F, and JJ conceived and designed the study. AS collected and analysed the data. AS and JJ wrote the draft manuscript. All authors interpreted the data, critically revised the draft for important intellectual content, prepared the manuscript, and gave final approval of the version to be published. AS is the guarantor.
Funding: JJ received funding for this study from the Swedish Research Council (project number K2009-61P-21304-04-4).
Competing interests: None declared.
Ethical approval: The regional ethics committee in Uppsala, Sweden (Nr 2004: M-496) approved the study.
Data sharing: No additional data available.
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.